Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2006-04-04
2006-04-04
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S188100, C424S208100, C530S350000, C530S333000, C530S344000, C530S345000, C530S826000
Reexamination Certificate
active
07022326
ABSTRACT:
This invention relates to retroviral regulatory proteins or fragments thereof, or interferon alpha protein or fragments thereof, which are carboxymethylated. This chemical modification leads to new proteins or fragments which are biologically inactive but preserve their immunogenicity (toxoids). These proteins or fragments thereof, or interferon alpha or fragments thereof, can be utilized in the treatment and prevention of retroviral infections. The invention also relates to a pharmaceutical composition comprising at least one carboxymethylated protein or fragment of the invention, together with a pharmaceutically acceptable carrier. The invention also relates to a vaccine comprising at least one of the carboxymethylated proteins or fragments of the invention, together with an immunologically acceptable carrier. The invention also relates to a process for obtaining an immunogenic yet not toxic retroviral regulatory protein or fragment, or interferon alpha or fragment. The invention also relates to a method of inducing an immune response in a mammal, comprising administering the vaccine of the invention to a mammal in an immunologically effective amount.
REFERENCES:
patent: 6132721 (2000-10-01), Zagury et al.
patent: 6200575 (2001-03-01), Zagury et al.
patent: 6420141 (2002-07-01), Zagury et al.
patent: WO 86/06414 (1986-11-01), None
patent: WO 91/18454 (1991-11-01), None
patent: WO 94/15634 (1994-07-01), None
patent: WO 95/31999 (1995-11-01), None
patent: WO 96/27389 (1996-09-01), None
patent: WO 99/33872 (1999-07-01), None
Kirsch, T., et al., “Cloning, High-Yield Expression inEscherichia coliand Purification of Biologically Active HIV-1Tat Protein,”Protein Expression and Purification 8:75-84, Academic Press, Inc (1996).
Protzman, W.P., et al., “Immunoradiometric Assay of a Recombinant Human Alpha-2 Interferon (SCH 30500),”J. Clin. Microbiol. 22:596-599, American Society for Microbiology (1985).
Aldridge, D.R. et al., “Binding of Nef to Cellular Kinases In Vitro Is Redox-Dependent,”Annu. Conf. Australasian Soc. HIV Med. 9:125-125, Poster No. P22 (1997).
Azad, A.A. et al., “Large-scale production and characterization of recombinant human immunodeficiency virus type 1 Nef,”J. Gen. Virol. 75:651-655 (1994).
Frankel, A.D. and C.O. Pabo, “Cellular Uptake of the Tat Protein from Human Immunodeficiency Virus,”Cell 55:1189-1193 (1988).
Goeddel, D.V. et al., “The structure of eight distinct cloned human leukocyte interferon cDNAs,”Nature 290:20-26 (1981).
Gringeri, A. et al., “A Randomized, Placebo-Controlled, Blind Anti-AIDS Clinical Trial: Safety and Immunogenecity of a Specific Anti-IFNα Immunization,”J. Acquired Immune Deficiency Syndromes 7:978-988 (1994).
Gringeri, A. et al., “Absence of Clinical, Virological, and Immunological Signs of Progression in HIV-1-Infected Patients Receiving Active Anti-Interferon-α Immunization: A 30-Month Follow-Up Report,”J. Acquired Immune Deficiency Syndromes and Human Retroviral. 13:55-67 (1996).
Norley, S. and R. Kurth, “Vaccination against HIV,”Immunobiol. 184:193-207 (1992).
Moy, P. et al., “Tat-Mediated Protein Delivery Can Facilitate MHC Class I Presentation of Antigens,”Molecular Biotechnol. 6:105-113 (1996).
Quan, N. et al., “In vivo Induction of Interleukin-1 Bioactvity in Brain Tissue after Intracerebral Infusion of Native gp120 and gp160,”Neuroimmunomodulation 3:56-61 (1996).
Spanjaard, R.A. et al., “The cysteines in position 1 and 86 of rat interferonβ1are indispensable for antiviral activity,”FEBS Letters 249:186-188 (1989).
Weissmann, C. and H. Weber, “The Interferon Gens,”Prog. Nucl. Acids Res.&Molec. Biol. 33:251-301 (1986).
Zagury, J.-F. et al., “A critical role of Tat and IFNα in the HIV-1-induced immunosuppression leading to AIDS,”Cellular Pharmacol. 3:97-103 (1996).
Zagury, D. et al., “Interferon β and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS,”Proc. Natl. Acad. Sci. USA 95:3851-3856 (1998).
Zoon, K.C., “Human Interferons: Structure and Function,”Interferon 9, Ion Gresser, ed., Academic Press Inc. Ltd., London, England, pp. 1-12 (1987).
Rappaport, J., et al., “HIV-1 TAT Toxoid: Rationale for a TAT Vaccine and Results of a Phase I Clinical Trial,”J. Neurol. 4:364 (1998).
Supplementary European Search Report for EP 98 96 4219, (Aug. 2000).
Carcagno Miguel
Rappaport Jay
Zagury Jean-François
Biovacs, Inc.
Neovacs
Sterne Kessler Goldstein & Fox P.L.L.C.
Stucker Jeffrey
LandOfFree
Carboxymethylated retroviral regulatory proteins and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carboxymethylated retroviral regulatory proteins and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxymethylated retroviral regulatory proteins and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3602392